Imugene Limited (IUGNF)

Imugene Limited (IUGNF) Stock Price & Analysis


IUGNF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.02 - $0.14
Previous Close$0.07
Average Volume (3M)202.66K
Market Cap
Enterprise Value$411.54M
Total Cash (Recent Filing)AU$99.89M
Total Debt (Recent Filing)AU$673.43K
Price to Earnings (P/E)-16.8
Feb 28, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding7,164,974,859
10 Day Avg. Volume206,745
30 Day Avg. Volume202,662
Standard Deviation0.72
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Ownership Overview

2.35% Mutual Funds
3.61% Other Institutional Investors
85.34% Public Companies and
Individual Investors


What was Imugene Limited’s price range in the past 12 months?
Imugene Limited lowest stock price was $0.02 and its highest was $0.14 in the past 12 months.
    What is Imugene Limited’s market cap?
    Currently, no data Available
    When is Imugene Limited’s upcoming earnings report date?
    Imugene Limited’s upcoming earnings report date is Feb 28, 2024 which is in 86 days.
      How were Imugene Limited’s earnings last quarter?
      Imugene Limited released its earnings results on Aug 25, 2023. The company reported $0 earnings per share for the quarter, the consensus estimate of $0 by $0.
        Is Imugene Limited overvalued?
        According to Wall Street analysts Imugene Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Imugene Limited pay dividends?
          Imugene Limited does not currently pay dividends.
          What is Imugene Limited’s EPS estimate?
          Imugene Limited’s EPS estimate is $0.
            How many shares outstanding does Imugene Limited have?
            Imugene Limited has 7,164,975,000 shares outstanding.
              What happened to Imugene Limited’s price movement after its last earnings report?
              Imugene Limited reported an EPS of $0 in its last earnings report, expectations of $0. Following the earnings report the stock price went up 25%.
                Which hedge fund is a major shareholder of Imugene Limited?
                Currently, no hedge funds are holding shares in IUGNF


                Company Description

                Imugene Limited

                Imugene Ltd specializes is a clinical-stage immuno-oncology company. Its product includes HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being Research, Development, and Commercialisation of oncolytic immunotherapies.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                ImmunoCellular Therapeutics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis